Ying Cheng

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

Baohui Han, Kai Li, Qiming Wang et al. · JAMA Oncology · 2018 · 620 citations · Full text

Medicine, Oncology, Pharmacology +17

The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial

Lili Wang, Zhen He, Sen Yang et al. · Translational Lung Cancer Research · 2019 · 36 citations · Full text

Medicine, Oncology, Pharmacology +13

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial

Ying Cheng, Baohui Han, Kai Li et al. · Cancer Medicine · 2020 · 33 citations · Full text

Medicine, Oncology, Pharmacology +15

Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial

Ying Cheng, Qiming Wang, Kai Li et al. · Cancer Medicine · 2021 · 21 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

P2.12-26 The Impact of Anlotinib for Relapsed SCLC Patients with Brain Metastases: A Subgroup Analysis of ALTER 1202

Ying Cheng, Q. Wang, K. Li et al. · Journal of Thoracic Oncology · 2019 · 11 citations · Full text

Medicine, Oncology, Pharmacology +14